Introduction
The enhanced frequency of p53 mutations in human tumors suggests that loss of p53 function contributes to cellular transformation (reviewed in Soussi, 2001) . However, it is generally unknown when during tumor progression p53 becomes mutant. Activation of p53, either as a result of oncogene expression or following chemical or radiation-induced DNA damage, leads to selection for cells with loss of p53 function, albeit with dierent kinetics and by dierent mechanisms. Oncogenes which function as primary transforming events, including c-myc , E1A (de Stanchina et al., 1998) and Ras (Palmero et al., 1998) , activate p53 by inducing p19ARF. P19ARF binds and inactivates mdm-2, a proto-oncogene that mediates the degradation of p53, resulting in accumulation of p53 in the nucleus (reviewed in Sherr, 1998; Prives, 1998) . Alternatively, DNA damage which usually occurs late in disease progression activates p53 via the ATM signaling pathway (reviewed in Khanna, 2000) . Therefore, the point during tumor progression at which p53 becomes active varies, depending on the mechanism of activation, suggesting dierent tumor suppressor roles for p53 in the progression of dierent tumors.
Erythroleukemias induced in mice infected with the Friend retroviral complex represent a well-characterized model in which to assess the role of p53 function in tumor progression (reviewed in Ben- David and Bernstein, 1991; Ney and D'Andrea, 2000) . Friend virus consists of a replication-defective spleen focus-forming virus, SFFV, and the replication-competent Friend murine leukemia virus, F-MuLV. Two strains of SFFV exist, the anemia-inducing strain SFFV A (FVA) and the polycythemia-inducing strain SFFV P (FVP), both of which cause disease in adult mice when complexed with F-MuLV. Infection with F-MuLV alone is implicated in disease in newborn rather than adult mice (Silver and Kozak, 1986) . Susceptible mice infected with either FVA or FVP develop a multi-stage disease that varies in progression depending on the strain used. The ®rst stage occurs 2 weeks post-infection, regardless of viral strain, and results from expression of the gp55 protein from SFFV. Gp55 binds to and activates the erythropoietin (Epo) receptor (Li et al., 1990 (Li et al., , 1995 leading to polyclonal expansion of preleukemic erythroblasts at the colony forming unit-erythroid (CFU-E) stage of development. Preleukemic erythroblasts retain their ability to dierentiate in vitro in the presence (FVA) or absence (FVP) of Epo. The second stage of disease is characterized by clonal expansion of transformed erythroblasts that are Epo-independent and emerge 3-5 (FVP) or 8-12 (FVA) weeks postinfection (Mager et al., 1981) . Transformation depends in part on SFFV viral integration upstream of the ets transcription factor PU.1 (Paul et al., 1989; MoreauGachelin et al., 1990 MoreauGachelin et al., , 1988 leading to overexpression of PU.1 mRNA (Moreau-Gachelin et al., 1989 and a subsequent block in dierentiation (Schuetze et al., 1993; Moreau-Gachelin et al., 1996; Yamada et al., 1997) .
Several lines of evidence demonstrate that p53 mutations are also associated with transformation in Friend virus-induced erythroleukemias. First, cloned murine erythroleukemic (MEL) cell lines derived from FVA (Munroe et al., 1988; Koury et al., 1997; Mowat et al., 1985; Chow et al., 1987) or FVP (Rovinski et al., 1987; Ben David et al., 1988; Mowat et al., 1985; Hicks and Mowat, 1988; Chow et al., 1987) -infected mice were originally reported to have p53 mutations resulting from deletions (Rovinski et al., 1987; Ben David et al., 1988; Munroe et al., 1988) , point mutations (Munroe et al., 1990; Koury et al., 1997) or retroviral insertions (Ben David et al., 1988; Mowat et al., 1985; Hicks and Mowat, 1998; Chow et al., 1987) in up to 95% of established lines. Although these data strongly support a role for loss of p53 function in immortalization and growth of transformed cells in culture, they do not provide information about the p53 status of the primary tumor. Second, a temperaturesensitive mutant of p53, when introduced into MEL cells lacking functional p53, resulted in enhanced sensitivity to Epo and increased b-globin production (Johnson et al., 1993) , G 1 growth arrest and apoptosis (Johnson et al., 1993; Ryan et al., 1993) . These studies suggested that re-introduction of wild type p53 into cells that had lost p53 function reversed the transformed phenotype by promoting dierentiation and/or cell death. However, reintroduction of exogenous wild type p53 into cultured MEL cells may not be representative of the cellular context in which endogenous p53 protein became active, and subsequently selected against, in the natural progression of the tumor. Third, transgenic mice expressing a dominant negative form of p53, p53 , had accelerated progression to erythroleukemia compared to wild type control animals when infected with FVP, suggesting that loss of p53 function was involved in disease progression in vivo (Lavigueur and Bernstein, 1991) . However, interpretation of the data from this study was complicated by the fact that the p53 mutation used was shown to have oncogenic properties independent of its ability to inhibit wild type p53 (Munroe et al., 1990) . Fourth, newborn p53 null mice infected with F-MuLV died signi®cantly earlier than wild type littermate controls (Wong et al., 1999) , also suggesting that loss of p53 function was involved in disease progression in vivo. However, when primary tumors from F-MuLV-infected p53 wild type or heterozygous mice were examined, many were found to have retained wild type p53 alleles (Wong et al., 1999; Howard et al., 1993) . Therefore, none of the studies described above have conclusively established a role for p53 in the natural progression of Friend virusinduced erythroleukemia in vivo.
In the current study we used a Friend virus-sensitive, p53-null mouse model to examine the role of p53 in progression of FVP-induced erythroleukemia in vivo. We provide conclusive evidence that loss of p53 function occurs during the natural progression of the tumor in vivo. Secondly, we demonstrate that the diseases arising in p53 wild type or null mice are biologically distinct, suggesting that the order of mutation is important in disease progression. Finally, our results demonstrate that the tumor suppressor function of p53 that is selected against during disease progression is not likely to be associated with genomic stability. The studies provide justi®cation for further investigation of the temporal order of p53 mutation and the mechanism of p53 activation that leads to the strong selection for cells with loss of p53 function in FVP-induced Friend erythroleukemia.
Results

Decreased survival of FVP-infected p53 null mice
To determine if loss of wild type p53 contributes to progression of Friend erythroleukemia in vivo, p53+/+, p53+/7 or p537/7 mice averaging 10 weeks of age were infected with the FVP strain of Friend virus and monitored for survival. Figure 1A demonstrates that p537/7 mice survived for a signi®cantly shorter time (P50.01) than did p53+/+ or p53+/7 mice. No signi®cant dierence in survival rates was observed between p53+/+ and p53+/7 mice. Since a substantial portion of p537/7 mice develop spontaneous lymphomas and other lethal tumors by 3 to 6 months of age (reviewed in Donehower, 1996) , we monitored survival of age and sex-matched uninfected control mice of all genotypes. Figure 1B demonstrates that approximately 15% of uninfected p537/7 mice died during the period of observation (up to 20 days postinfection) in which 100% of FVP-infected p537/7 mice died (compare p537/7 survival in Figure 1A ,B at 20 days). No decrease in survival was observed in either p53+/+ or p53+/7 uninfected mice over the period of observation indicated. The data demonstrate that FVP-infected p537/7 mice experience accelerated death compared to p53+/+ or p53+/7 controls and suggest that the majority of deaths are attributable to Friend virus infection.
FVP-infected mice die of erythroleukemia
To exclude the possibility that p537/7 mice were more susceptible to death resulting from the hepatosplenomegaly characteristic of the ®rst stage of Friend disease, we evaluated the size of spleens and livers of p53+/+ and p537/7 animals during the ®rst 2 weeks post-FVP infection. No correlation between genotype and spleen or liver weight was observed (data not shown). Likewise, the incidence of ruptured organs in infected mice at the time of their death was rare and also showed no correlation with genotype. These observations demonstrated that p537/7 mice were not dying disproportionately as a consequence of hepatosplenomegaly, supporting a previous observation that p53 function is not involved in early-stage Friend disease (Lavigueur and Bernstein, 1991) , and suggesting that most of the deaths resulted from endstage erythroleukemia.
Con®rmation that the majority of mice were dying of erythroleukemia was provided by hematological and histopathologic examination of tissues from FVPinfected and control animals. The average changes in peripheral blood values of infected animals of all genotypes were consistent with the onset of leukemia (data not shown) as previously reported (Tambourin et al., 1973; Moreau-Gachelin et al., 1996; Koury et al., 1997) . In general, blood value changes included a decrease in RBC, hematocrit and platelet values and an increase in the WBC. Since each of these changes were not consistently observed in a single mouse, we adapted the criteria of Koury et al. (1997) to establish a de®nitive diagnosis of leukemia based on blood values and physical symptoms. A diagnosis of leukemia was made if the animal exhibited three of the following criteria: WBC 440610 Figure 1 Survival of FVP-infected and control p53+/+, p53+/7 and p537/7 mice. p53+/+ (n=36; black line), p53+/7 (n=20; dashed line) or p537/7 (n=20; gray line) mice of approximately 10 weeks of age were infected with FVP (A) or uninfected (B) and monitored for survival for the time indicated. The uninfected p53+/+ and p53+/7 curves are superimposed. The probability of survival, as determined by Kaplan-Meier survival analysis, is plotted aspirates from the control mouse contained an abundance of mature neutrophils ( Figure 2A ) that were replaced with immature blast cells in the leukemic animal ( Figure 2D ). The spleens of leukemic animals showed loss of normal splenic architecture ( Figure 2E ) when compared to control animals ( Figure 2B ), as a result of in®ltration of leukemic blasts. Finally, livers from leukemic animals exhibited enlarged sinusoids with in®ltrating blasts ( Figure 2F ), which were not present in liver tissue from control animals ( Figure  2C ). Since leukemias are rare among the spectrum of spontaneous tumors that develop in p537/7 mice (Harvey et al., 1993; Donehower et al., 1992; Jacks et al., 1994) , we conclude that development of erythroleukemia was attributable to Friend virus infections.
p53 gene mutations in primary tumors of p53+/7 and p53+/+ mice Decreased survival of FVP-infected p537/7 mice compared to wild type controls demonstrates that germ line loss of p53 cooperates with Friend virus infection to accelerate progression to end-stage erythroleukemia; however the data do not demonstrate that p53 mutations are required for FVP-induced erythroleukemia in vivo. To address this question, primary tumor samples were isolated from the spleens of con®rmed leukemic p53+/+ and p53+/7 mice (using the criteria described above), and examined for mutations in p53 transcripts. Table 1 demonstrates that p53 mutations were observed (as deletions, insertions or point mutations) in every tumor sample tested. Point mutations representing non-synonymous codon changes were the most frequent ®nding. Together the data strongly support the conclusion that mutation of p53 is a requirement for the in vivo progression of Friend virus-induced erythroleukemia rather than solely as a consequence of derivation of leukemic cell lines.
p53 null mice have accelerated onset of erythroleukemia and decreased survival following diagnosis
Experiments were performed to determine if the order of mutation aected the biological disease that results in FVP-infected mice. It has been suggested that overexpression of PU.1 precedes loss of functional p53 in the development of murine erythroleukemia. Speci®cally, transgenic mice expressing high levels of PU.1 protein develop erythroleukemia in which loss of functional p53 occurs late or not at all during the progression of the disease (Barnache et al., 1998; Moreau-Gachelin et al., 1996) . Using the diagnostic criteria established above we compared the onset of leukemia in FVP-infected p53+/+ and p537/7 mice, in which the order of PU.1 and p53 mutations is reversed. Figure 3A demonstrates that a higher percentage of p537/7 mice developed erythroleukemia compared to wild type controls, at all time points observed during the early weeks post-infection. No signi®cant dierence in the onset of erythroleukemia was observed between p53+/+ and p53+/7 mice (data not shown). The results demonstrate that the onset of Friend virus-induced erythroleukemia is accelerated in p53 null animals compared to wild type controls. Once a diagnosis of leukemia was made, the infected mice were followed for survival. Figure 3B demonstrates that p537/7 mice succumbed to their disease signi®cantly faster than p53+/+ mice (P=0.047). The data suggest that p537/7 mice experience a biologically more aggressive disease than wild type littermate controls.
Tumor burden is enhanced in p53 null mice
Enumeration of tumor colony formation was assessed as a quantitative means to evaluate tumor onset and burden in erythroleukemic mice. Spleen cells were isolated from virally-infected p53+/+ or p537/7 animals at the indicated times and assayed in methylcellulose culture medium for the presence of tumor cells capable of forming colonies (CFU-FVP) in the absence of growth factors (Mager et al., 1981) . Figure 4 demonstrates that tumor colonies were not detected in the spleens of uninfected control mice of either genotype (0 weeks post-infection) but were apparent by 1 week post-infection in the spleens of both wild type and null animals. Greater numbers of CFU-FVP were isolated from p537/7 mice 1 week post-infection as compared to p53+/+ mice (an average of 26 versus nine colonies per 5610 6 nucleated spleen cells, respectively). By 2 weeks post-infection the average number of CFU-FVP in the spleens of p537/7 animals was substantially greater than that observed in p53+/+ animals (122 versus 14 per 5610 6 nucleated spleen cells, respectively). Continued monitoring for CFU-FVP in p53+/+ mice demonstrated that the average number of colonies observed remained relatively constant out to 6 weeks post-infection and did not approach the number of colonies observed in p537/7 mice at 2 weeks post-infection (data not shown). The data demonstrate that Friend virusinfected p537/7 mice have an increased tumor burden in vivo compared to infected p53+/+ animals. These data are consistent with the earlier onset of disease and more rapid death post-diagnosis that was observed in p537/7 mice (Figure 3) . Further the data suggest that additional mutations occur in cells of FVP-infected p537/7 mice that confer a growth advantage which contributes to transformation.
Derivation of cell lines is enhanced from tumor colonies originating from p53 null animals
To further investigate the nature of the leukemias arising in FVP-infected mice, we attempted to establish cell lines (Fvp lines) from CFU-FVP tumor colonies originating from p53+/+, p53+/7 or p537/7 animals. In general, Fvp lines could not be derived from CFU-FVP colonies isolated from p53 +/+ and p53+/7 mice until 4 and 3 weeks post-infection, respectively. In contrast, cell lines were easily generated from CFU-FVP colonies isolated from p537/7 mice by 2 weeks post-infection. Table 2 demonstrates that the derivation frequency for Fvp lines derived from CFU-FVP colonies originating from p537/7 mice was 24-fold higher than that of CFU-FVP colonies originating from p53+/+ mice (24% versus 1%, respectively). Derivation of Fvp lines from p53+/7 mice occurred at an intermediate level (5%) but was more similar to the derivation frequency observed with p53+/+ mice. Since p53 was shown to be mutant in all primary tumors evaluated from p53+/+ and p53+/7 mice, the absence of p53 alone is not responsible for enhanced ability to derive cell lines from p537/7 mice. Likewise, since cell lines could not be derived from every CFU-FVP colony grown from p537/7 mice, loss of p53 alone is insucient for immortalization of Friend virus-infected cells. Therefore, the data demonstrate that additional genetic mutations arise earlier in tumors derived from p537/7 versus p53+/+ mice, most likely as a consequence of loss of p53 tumor suppressor function in maintaining genomic stability, allowing a growth advantage to cells both in vivo and in vitro.
Overexpression of PU.1 is not a universal finding in cell lines derived from p53 null mice Evidence that cell lines derived from p537/7 CFU-FVP colonies were genetically distinct from those arising from p53+/+ colonies was provided by analysis of PU.1 mRNA expression. It has been shown previously that PU.1 mRNA is overexpressed in 100% , 1990, 1989) . In the vast majority of cases (60% (Koury et al., 1997) 72% (Paul et al., 1989) and 95% (Moreau-Gachelin et al., 1988 ), PU.1 overexpression occurs as a result of SFFV integration upstream of the PU.1 locus resulting in gene rearrangement, which can be detected by Southern blot analysis. The variability from study to study may result from the use of dierent restriction enzymes to digest the DNA. Likewise, the inability to ®nd PU.1 gene rearrangement in 100% of cell lines tested in the various studies may result from the use of a limited panel of restriction enzymes. Alternatively, mechanisms not previously described may explain the elevated levels of PU.1 mRNA in the absence of SFFV integration into the PU.1 locus. Since Southern blot analysis of PU.1 gene rearrangement is not reliable as an indicator of upregulated expression of PU.1, we analysed cell lines for PU.1 mRNA expression by Northern blot analysis. Figure 5 is a representative blot of mRNA isolated from cell lines derived from p53+/+ (three of eight) and p537/7 (seven of 43) mice. b-globin mRNA expression con®rmed that the vast majority of lines derived were erythroid in nature ( Figure 5C ). Cell lines that did not express b-globin mRNA ( Figure  5C , lane 5) were not considered in the analysis. In total, 8/8 (100%) erythroid cell lines derived from p53+/+ mice expressed PU.1 mRNA, whereas only 31/43 (72%) erythroid cell lines derived from p537/7 mice expressed PU.1 mRNA. An established MEL cell line ( Figure 5B , lane 12) and the non-transformed counterpart to Fvp lines (FVP cells isolated from the ®rst stage of Friend disease) ( Figure 5B , lane 11) were included as positive and negative controls for PU.1 expression, respectively. The non-speci®c band detected in all cell lines most likely represents Spi-B, another ets family transcription factor with 43% amino acid identity with PU.1 (Ray et al., 1992) . In summary, the data demonstrate that the order of PU.1 and p53 mutation is important in the progression of Friend erythroleukemia and in the total tumor burden and survival of the animals. The dierent derivation frequencies and gene expression pro®les of tumor cell lines isolated from p53 wild type and null mice provide conclusive evidence that the diseases are genetically and distinct.
Discussion
In the current study we set out to analyse the role of p53 in the in vivo progression of Friend virus-induced erythroleukemia in mice of an enriched Balb/c background. We took the direct approach of infecting p53 wild type and null mice with the FVP strain of Friend virus and assessed the animals for tumor onset, survival and the p53 status of the primary tumors that developed. Our hypothesis was that if p53 loss-offunction were required for the in vivo progression of Friend leukemia, then providing the p53 mutation a priori would accelerate disease progression. Secondly, we hypothesized that primary tumors derived from 3) and p537/7 (lanes 4 ± 10) mice, from nontransformed splenic erythroblasts isolated from pre-leukemic FVP-infected p53+/+ mice (lane 11) or from an established MEL cell line (lane 12). Gel electrophoresis was performed and ethidium bromide-stained total RNA was photographed as a control for loading (A). Northern blot analysis was performed using radiolabeled cDNA probes to PU.1 (B) or b-globin (C). NS represents a non-speci®c band detected in all cell lines tested, including known PU.1-negative NIH3T3 cells (data not shown) FVP-infected p53+/7 or p53+/+ mice would have mutant p53 alleles if loss of p53 function were required for disease progression. Our studies demonstrated that p53 null mice succumbed to erythroleukemia sooner than wild type or heterozygous animals. Importantly, we demonstrated that the majority of infected mice of all genotypes died of virally induced erythroleukemia by documenting their diagnosis with hematological and histopathologic analyses. Analysis of p53 transcripts isolated from primary tumors of FVP-infected heterozygous or wild type mice revealed that in all cases mutations and/or deletions were found, many in thè hot spot' region of the p53 gene, consisting of exons 5 ± 8, previously shown to be the target of mutational deregulation in multiple human tumors (reviewed in Soussi, 2001; Hainaut and Holstein, 2000) . Together the data demonstrate that loss of p53 function is a requirement for the progression of Friend disease in vivo. In this regard, our data dier from that reported by Howard et al. (1993) and Wong et al. (1999) in which the majority of primary tumors isolated from p53 wild type or heterozygous mice infected with FMuLV retained wild type p53 alleles. However, in both studies, the majority of cell lines derived from primary tumors failed to express wild type p53 alleles. The authors concluded that loss of p53 function was required for growth and immortalization of Friend cell lines in vitro but were unable to de®ne the role of p53 in the progression of the disease in vivo. The dierences in the current study and those previously reported may result from the method of p53 genotyping used for the primary tumors. We employed PCR analysis, which allowed detection of point mutations as well as deletions, whereas Howard et al. (1993) and Wong et al. (1999) employed Southern blot analysis, which would be more likely to detect deletions rather than point mutations. Alternatively, the dierences may re¯ect the use of dierent viruses since F-MuLV integrates into Fli-1 rather than PU.1 and causes disease in newborn rather than adult mice. In summary, the current study unequivocally clari®es the role of p53 in the natural progression of FVP-induced Friend erythroleukemia in vivo.
Data from a variety of model systems suggest that activation of the ets gene (PU.1 in FVA or FVP infection (Barnache et al., 1998; Quang et al., 1997) or Fli-1 in F-MuLV infection (Howard et al., 1993) ), precedes inactivation of p53 during progression of Friend virus-induced erythroleukemias. Several aspects of our study demonstrate that the erythroleukemia that results in FVP-infected mice is biologically and genetically distinct when the order of PU.1 and p53 mutation is reversed. First, FVP-infected p53 null mice exhibited an earlier onset of disease, a greater tumor burden and decreased survival post-diagnosis compared to wild type animals. Second, the frequency of derivation of cell lines was greatly enhanced from p53 null versus wild type mice. Third, analysis of the derived cell lines revealed that 28% versus 0% of bglobin-positive cell lines derived from p53 null versus p53 wild type mice, respectively, failed to express PU.1 mRNA. Several aspects of our study dier from the ®ndings of Lavigueur and Bernstein (1991) and Howard et al. (1996) in which transgenic mice expressing dominant negative p53 were infected with FVP or F-MuLV, respectively. In contrast to the current report these studies found similar rates of erythroleukemia development (Howard et al., 1996) , similar numbers of tumor colonies isolated (Lavigueur Benstein, 1991) and comparable numbers of PU.1 gene rearrangement in cell lines isolated from transgenic versus wild type mice (Lavigueur and Benstein, 1991) . The results led the authors to conclude that it is the accumulation of molecular events rather than the order of mutation that is important during leukomogenesis. It is likely that the dierences observed between our studies and those described above are associated with the nature of the p53 mutation used, in addition to the dierent genetic backgrounds of the mice. Several lines of evidence suggest that expression of the mutant and null p53 alleles would not be equivalent. Speci®cally, the reported gain-of-function activities for the mutant used in the Lavigueur and Bernstein study (Munroe et al., 1990) and the dierent tumor spectrum and incidence of spontaneous tumors in p53 mutant (Lavigueur et al., 1989) versus null (Donehower et al., 1992) mice suggest that the dominant negative and null mutations result in biologically dierent tumors.
Together, our data suggest that additional hits occur in cells derived from p53 null mice that result in enhanced cell growth both in vivo and in vitro, resulting in a more aggressive disease phenotype. Further, the data demonstrate that mutations other than activation of PU.1 can contribute to development of erythroleukemia in p53 null mice. We conclude that loss of p53 function as a primary event in FVP-induced tumor progression results in accumulation of mutations that provide cells with enhanced growth and/or survival potential, leading to a biologically more aggressive disease. Thus the temporal order of mutation appears to be an important parameter in the pathogenesis of end-stage Friend erythroleukemia.
The data presented in this study provide evidence that loss of p53 function is selected for during the natural progression of Friend erythroleukemia in vivo. The tumor suppressor activity that leads to selection for p53 mutations during progression of Friend erythroleukemia is unknown. The current study demonstrates it is unlikely that maintenance of genomic stability represents the tumor suppressor function selected against in Friend disease. We conclude this from the observation that wild type p53 mice developed a disease that appeared to be more genetically stable than that observed in p53 null mice. In the latter case, in the absence of p53 a priori, genomic instability may have contributed to expression of oncogenes or inhibition of tumor suppressor genes, distinct from PU.1, which provided a growth advantage to p53 null cells in vitro. We have considered that other activities of p53 may represent the tumor suppressor function(s) selected against in Friend erythroleukemia. First, overexpression of PU.1, in the presence or absence of gp55, may lead to p53 activation and sensitize cells to p53-mediated apoptosis under conditions of limiting growth factor. In that regard, Quang et al. demonstrated that primary ts-vSea-infected avian erythroblasts expressing wild type p53, an activated Epo receptor and PU.1 were more susceptible to apoptosis following removal of Epo from the culture than were similar cells expressing dominantnegative temperature-sensitive p53 (Quang et al., 1997) . Second, we previously reported that p53 becomes transcriptionally active during dierentiation of preleukemic erythroblasts (Kelley et al., 1998) , supporting a role for p53 in terminal erythroid dierentiation and thus providing selective pressure for p53 mutation in erythroid transformation. Future experiments designed to determine the mechanism and kinetics of p53 activation during progression of Friend erythroleukemia should resolve which of the tumor suppressor functions described above is responsible for the strong selection for p53 mutant cells.
Materials and methods
p53-deficient mice
Male heterozygous p53-de®cient 129/Sv-Trp mlTyj mice, generated by germline disruption of the p53 gene by replacement of exons 2 through 6 with a bacterial neo gene (Livingstone et al., 1992) , were obtained from Jackson Laboratories, Bar Harbor, ME, USA. The p53 deletion mutation was backcrossed to the F 5 generation in the Friend virus-sensitive Balb/c strain containing wild type p53. Progeny were genotyped from blood obtained by retro-orbital bleeds using a four primer PCR assay to distinguish between wild type and deleted p53 alleles as previously described (Kelley et al., 1998) . The F 5 colony was maintained by breeding heterozygous animals. Female p53+/+, p53+/7 or p537/7 mice were used for all experiments.
Blood values
RBC, WBC, platelet and hematocrit values were evaluated on peripheral blood collected in capillary tubes from retroorbital eye bleeds using a System 9010+CP cell counter (Serono Diagnostics, Inc., Allentown, PA, USA). Each assay was performed in duplicate and the average value determined.
Induction of tumors
Female F 5 p53+/+, p53+/7 or p537/7 mice of approximately 10 weeks of age were infected via tail vein injection with 0.20 ml of a 1 : 250 dilution of the polycythemia-inducing strain of Friend virus, F-MuLV/SFFV AP -L (V-406) (generously provided by Dr Sandra Ruscetti, National Cancer Institute, Frederick, MD, USA). The viral supernatant was produced by collection of media from retrovirally infected NIH3T3 cells grown in Dulbecco's modi®ed Eagle's medium (D-MEM) with 10% FCS, 100 U/ml penicillin and 100 mg/ml streptomycin. Viral titers were determined by infecting mice of the same age (approximately 10 weeks) with varying dilutions of supernatant and monitoring mice for development of splenomegaly and erythroleukemia. A diagnosis of leukemia was established if the animal exhibited three of the following criteria: WBC 440610 6 /ml, RBC 56.5610 9 /ml, platelet 5300610 6 /ml, hematocrit 530%, and/or physical symptoms such as diculty in breathing, unkempt fur, or cold, pale ears and feet.
Histopathology
Tissue samples (bone marrow, spleen and liver) were obtained from uninfected control or FVP-infected mice that had been diagnosed with leukemia based on hematological and physical symptoms as described above. Slides were prepared from tissue samples and stained with WrightGeimsa (bone marrow) or hematoxylin and eosin (spleen and liver) and evaluated by an experienced hematopathologist.
p53 sequencing
Leukemic spleens from p53+/+ or p53+/7 mice were surgically removed and aseptically pulverized to yield single cell suspensions. RNA was collected from 10610 6 nucleated cells. cDNA was generated utilizing the Thermoscript RT ± PCR System (Life Technologies, Gaithersburg, MD, USA) for the 5' end of the gene using an antisense primer speci®c for exon 8(AB12): 5' AACACGAACCTCAAAGCT, corresponding to nt 873?991 (Munroe et al., 1990) . The coding region extending between exons 1 ± 8 was then ampli®ed using primer AB12 and sense primer 53-2 (speci®c for exon 1): 5'-AAGCTTGCATTCAGGCCCTCATCCTCC, corresponding to nt 93?119 (Munroe et al., 1990) . The 872 base pair product was cleaned using the QIAquick PCR Puri®cation Kit (QIAGEN, Santa Clarita, CA, USA) and sequenced by the DNA Sequencing Facility (University of Utah, Salt Lake City, UT, USA) using both the AB12 and 53-2 primers. All mutations were con®rmed by bi-directional sequencing.
Tumor colony assay FVP-infected or uninfected p53+/+ or p537/7 mice were sacri®ced at the times indicated and their spleen cells assayed for the presence of transformed cells capable of giving rise to colonies (CFU-FVP) in methylcellulose media, as described by Mager et al. (1981) . Brie¯y, the spleens were surgically removed and aseptically pulverized to yield single cell suspensions. A total of 1.5610 7 viable, nucleated cells from each animal were plated in media containing 2% methylcellulose (Sigma, St. Louis, MO, USA), 30% heat-inactivated FCS, 100 U/ml penicillin, 100 mg/ml streptomycin and 20 mM 2-mercaptoethanol, in the absence of exogenous growth factors. Cultures were maintained for 14 days at 378C in 5% CO 2 . The number of CFU-FVP colonies containing at least 2610 4 cells was scored with the aid of an inverted microscope. Plating eciency was monitored by concomitant plating of an established MEL line.
Establishment of cell lines
Individual tumor colonies were plucked with the aid of an inverted microscope and transferred to 24-well plates in 500 ml of Iscove's modi®ed Dulbecco's medium (IMDM) containing 30% heat-inactivated fetal calf serum (FCS) (Hyclone Laboratories, Logan, UT, USA), 1% bovine serum albumin (BSA) (Intergen, Purchase, NY, USA), 100 U/ml penicillin, 100 mg/ml streptomycin, and 130 mM a-thioglycerol, in the absence of exogenously added growth factors. Plates were incubated at 378C in 5% CO 2 . Cultures were expanded as allowed. Brie¯y, 500 ml cultures were ®rst expanded to 1 ml and then to 2 ml, at which time they were transferred to 6-well plates. Two ml cultures were expanded to 3 ml and transferred to 25 cm 2 tissue culture¯asks. Cell lines were considered established when the culture reached 5 ml. All cell lines were established between 1 and 2.5 weeks from the time CFU-FVP colonies were put into liquid culture. RNA, protein and DNA samples were collected on all established cell lines, at the time of their initial expansion, for subsequent analyses. In addition, aliquots from the initial expansion were cryopreserved in 8% dimethyl sulfoxide in heat-inactivated FCS and stored in liquid nitrogen.
Northern blot analysis
Total RNA was collected from 10 7 cells by a single step guanidium thiocyanate-phenol method using Ultraspec TM RNA (Biotecx Laboratories, Houston, TX, USA) and electrophoretically separated in 1% agarose gels containing 0.66 M formaldehyde as described previously (Kelley et al., 1998) . Immediately before electrophoresis, 10 mg ethidium bromide (EtBr) was added to each sample. After electrophoresis the gels were photographed and blotted to ZetaProbe 1 GT Genomic Tested Blotting Membranes (Bio-Rad Laboratories, Hercules, CA, USA). Prehybridization and hybridization were performed in 50% formamide, 66SSC (16SSC=0.15 M NaCl, 0.15 M sodium citrate), 16Den-hardt's solution (0.02% Ficoll, 0.02% polyvinylpyrrolidone, 0.02% BSA) and 0.5% sodium dodecyl sulfate (SDS). The mouse b-globin cDNA probe was a PstI/PstI fragment containing the ®rst two exons of the b-major globin gene (Hofer and Darnell, 1981) . The PU.1 cDNA probe was an EcoRI fragment containing the entire coding region of PU.1 (Dr David Kabat, Oregon Health Sciences University, Portland, OR, USA). All probes were labeled by the random primer method using a7 32 P-dCTP (800 Ci/mmol). Hybridizations were performed at 428C for 16 h using 10 6 c.p.m. labeled probe per ml of hybridization buer. Blots were washed twice with 26SSC, 0.5% SDS at room temperature for 10 min, followed by two washes with 0.16SSC, 0.1% SDS at 558C for 40 min.
Statistical analyses
Kaplan-Meier analysis (Shibuya and Mak, 1982) was used to correlate the eect of p53 genotype on survival of FVPinfected mice. Signi®cant dierences in the survival curves were determined using the log rank test. Signi®cant dierences in survival post-diagnosis were determined using a Student's t-test.
